Research & Program News
The first infusion of an investigational drug that aims to delay or help to prevent the earliest memory loss due to Alzheimer’s disease took place in September at Butler Hospital in Providence, R.I., researchers announced.
The study seeks to identify new cognitive and neural biomarkers of preclinical Alzheimer’s disease, which would aid in earlier diagnosis and interventional treatment for the disease.
AHEAD 3-45 is a clinical trial for a treatment aimed at preventing cognitive decline in people with preclinical Alzheimer’s Disease (AD).
MAP Director Dr. Stephen Salloway, along with other international leaders in the fight against Alzheimer’s, talk with the Providence Journal and WJAR NBC10 about how the fight to end Alzheimer’s continues despite coronavirus.
Aducanumab, an investigational drug for the treatment for Alzheimer’s disease, has been submitted to the FDA for approval with a request for Priority Review. If approved, it would become the first therapy to reduce the clinical decline of Alzheimer’s disease.
RI Chosen as 1 of 5 Sites for First Nationwide Study of Lifestyle Intervention to Reduce Risk of Cognitive Decline
The U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) is sponsored by the Alzheimer’s Association and is the first such study to be conducted in a large, diverse group of Americans across the United States.
Louisa Thompson, Ph.D., research scientist at Brown University and Butler Hospital, will evaluate how app-based and online cognitive tests might be used to detect subtle changes in memory and thinking associated with Alzheimer’s.
Butler Hospital was one of 27 sites across the U.S. to study the drug flortaucipir through a partnership between its Memory and Aging Program and Rhode Island Hospital.
There may soon be a new tool available to more firmly diagnose Alzheimer’s disease, according to the results of a study recently published in JAMA Neurology and conducted in part at the Memory and Aging Program at Butler Hospital.
New Data for Investigational Drug for Early-Onset Alzheimer’s Illustrates Value of “Failed” Research Studies
Initial results in a clinical trial aimed at early-onset Alzheimer’s didn’t look promising – but upon further review, the data has spurred further study.
URI, BayCare and Butler Hospital to test retinal scanning for early detection of Alzheimer’s disease
Study seeks 330 volunteers for clinical trials.
On New Year's day GoLocalProv announced that it had selected Stephen Salloway, M.D. as its Man of the Year for 2019. Dr. Salloway, a world leader in Alzheimer's research, is director of Neurology and the Memory and Aging Program at Butler Hospital and Martin M. Zucker...
Major Alzheimer’s Association grant to enable researchers to test a drug that could slow the progression of Alzheimer’s disease.
Drug Studied at Butler Hospital’s Memory and Aging Program May Become First New Treatment for Alzheimer’s in 16 Years
Aducanumab maker Biogen seeking FDA review in early 2020; if approved, it will become the first drug to remove amyloid protein from the brain and slow the progression of Alzheimer’s disease (AD).
Dr. Hwamee Oh Named Director of Imaging Research for The Memory and Aging Program at Butler Hospital
Dr. Oh will research the use of imaging to detect Alzheimer’s before symptoms appear, offering patients a chance at early intervention.
Memory and Aging Program Director Dr. Stephen Salloway on the growing health crisis and how all Rhode Islanders ages 40 to 85 can help.
A look inside the Memory and Aging Program at Butler Hospital and how Southern New Englanders are contributing to the mounting battle against Alzheimer’s.
Clinical Trials Aimed at Preventing Alzheimer’s to Begin at Butler Hospital’s Memory and Aging Program
The Memory and Aging Program at Butler Hospital will launch trials of two new treatments aimed at preventing Alzheimer’s in early 2020.
Study: Amyloid Plaques in Brain Linked to Greater Growth of Tau “Tangles,” Development of Alzheimer’s
The study provides new insight into how plaques lead to cognitive decline and supports use of PET imaging to predict and diagnose dementia.
Stephen Salloway, MD, Global Leader in Alzheimer’s Research, Inducted Into Rhode Island Heritage Hall of Fame
Dr. Salloway and his team at the Memory and Aging Program at Butler Hospital are global leaders in the fight against Alzheimer’s.
The results of a landmark trial conducted in part at the Memory and Aging Program at Butler Hospital show that amyloid PET brain scan imaging significantly improves both the accuracy of diagnosis and the subsequent medical management of patients with mild cognitive impairment and dementia.
Memory and Aging Program Director Dr. Stephen Salloway, a study co-author, calls the findings a “game changer” in Alzheimer’s research.
The world’s first participant in an Alzheimer’s prevention study finished his 4 1/2-year clinical trial last month. Here’s what he has to say about the experience.
Major advances in the fight against Alzheimer's disease are on the horizon thanks to increasing support for research in recent years. An inspiring example of that support was on display locally on Saturday, November 10, when hundreds of people turned out...
This new study is currently enrolling people aged 40 – 64 with normal memory or early onset cognitive impairment. The goal is to better understand how and why some people develop this rare form of Alzheimer’s disease.